Advisory Committee on Immunization Practices recommends hepatitis A vaccination for children

October 26, 2005

ALEXANDRIA, VA - October 26, 2005 - The National Partnership for Immunization supports the unanimous decision of the Advisory Committee on Immunization Practices (ACIP) to recommend universal hepatitis A vaccination for all children in a single age cohort between 12 to 35 months, with catch-up vaccination through the pre-school years. Hepatitis A is one of the most commonly reported vaccine-preventable diseases in the country. We believe universal hepatitis A vaccination for children is an effective strategy to reduce disease incidence and applaud the Committee's decision.

"Comprehensive immunization policies are essential to our nation's health," said David Neumann, PhD, Executive Director of the National Partnership for Immunization. "Our ability to reduce the incidence of vaccine-preventable diseases, like hepatitis A, requires constant vigilance. This ACIP recommendation is an important step in reducing the incidence of hepatitis A disease in the U.S."

Children play an important role in hepatitis A transmission. Therefore, expanding childhood vaccination recommendations can be an effective strategy to help save lives and reduce the burden of hepatitis A disease in this country. Universal hepatitis A vaccination for children can also protect communities from the disease through "herd immunity."
About the National Partnership for Immunization
The National Partnership for Immunization (NPI) is a non-profit organization that was created in 2000 to encourage greater awareness, acceptance and use of immunization by people of all ages through partnerships with public and private organizations. NPI brings together private and public sector partners, including healthcare provider professional associations, community-based organizations, policymakers, vaccine manufacturers, insurance companies, managed care corporations, hospitals, major employers, healthcare and social service professionals, medical and scientific researchers and public health advocates to improve the effectiveness of public and professional educational and outreach efforts to reduce the incidence of vaccine-preventable diseases among children, adolescents and adults.

About Hepatitis A
Hepatitis A is a serious liver disease caused by the hepatitis A virus. This virus is found in the stool of persons with hepatitis A and is spread by close personal contact and by eating food or drinking water contaminated with the hepatitis A virus. Hepatitis A can be easily passed by those infected with the disease to others within the same household. According to the Centers for Disease Control and Prevention, hepatitis A incidence rates in children have been among the highest reported because they often come in close contact with infected children. About one in five people with the disease have to be hospitalized and up to 100 people with the disease may die each year. Symptoms of the disease can be debilitating and include fever, fatigue, loss of appetite, nausea, abdominal discomfort, jaundice and dark urine.

GlaxoSmithKline provided editorial and media relations assistance for this statement.

Cohn & Wolfe

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to